CN Patent

CN1228090A — 影响il－4和g－csf的二氮萘

Assigned to Merck Sharp and Dohme LLC · Expires 1999-09-08 · 27y expired

What this patent protects

描述式(Ⅰ)化合物或其药学上可接受的盐，其中E、Q、T、U、V、L、Z、X、W、M、Y和Y’如在此所定义。这些化合物用作治疗变态反应、炎症、自身免疫疾病、B－细胞淋巴瘤、肿瘤和骨髓移植后作用的药物。

USPTO Abstract

描述式(Ⅰ)化合物或其药学上可接受的盐，其中E、Q、T、U、V、L、Z、X、W、M、Y和Y’如在此所定义。这些化合物用作治疗变态反应、炎症、自身免疫疾病、B－细胞淋巴瘤、肿瘤和骨髓移植后作用的药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN1228090A
Jurisdiction
CN
Classification
—
Expires
1999-09-08
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.